European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading

MT Newswires Live
08 Jul

European equities traded in the US as American depositary receipts were trending higher late Tuesday morning, rising 0.74% to 1,491.35 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by semiconductor company Sequans Communications (SQNS) and biotech firm Evaxion (EVAX), which climbed 28% and 3.5%, respectively. They were followed by biopharmaceutical company Grifols (GRFS) and internet browser company Opera (OPRA), which increased 2.7% and 2.6%, respectively.

The decliners from continental Europe were led by biopharmaceutical company DBV Technologies (DBVT) and brewing company Anheuser-Busch InBev (BUD), which fell 2.5% and 1.3%, respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and consumer goods company Unilever (UL), which were off 0.8% and 0.7%, respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and pharmaceutical company Silence Therapeutics (SLN), which rose 4.6% and 3.8%, respectively. They were followed by biotech firm Autolus Therapeutics (AUTL) and oil and gas company BP (BP), which were up 2.9% and 2.6%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Trinity Biotech (TRIB), which lost 2.6% and 1.9%, respectively. They were followed by tobacco company British American Tobacco (BTI) and biopharmaceutical company Verona Pharma (VRNA), which were down 1.6% and 1.5%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10